A Phase 1 interventional study of acalabrutinib in Hepatic Impairment, Hepatic Insufficiency and Healthy Subjects, sponsored by Acerta Pharma BV. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-10.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.
Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 38th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2018, is one of 42 in phase 1, and was the 32nd registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Incyte Corporation · Sites in United States
Ages 18–80
Eli Lilly and Company · Sites in United States, Hungary
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 28 across the 48 interventional studies, 28 across the 3 observational. Of the 47 that completed or were terminated, 16 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 52 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
AstraZeneca has 2 studies filed under Hepatic Insufficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatic Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07401862Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | 2027-03 |
| NCT07559474Incyte CorporationA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment | 2027-04-13 |
| NCT07677358PfizerA Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease | 2027-08-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Hepatic Insufficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hepatic-Impaired Subjects Only:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.
Drug: acalabrutinib
Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.
Drug: acalabrutinib
A 50-mg single oral dose of acalabrutinib will be administered.
Plasma Acalabrutinib PK Parameters
Area Under the Concentration-Time Curve
Time frame: Severe HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 60, 72 hrs post-dose. Normal HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 hrs post-dose.
Maximum Plasma Acalabrutinib Concentration
Maximum Cmax
Time frame: Severe HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 60, 72 hrs post-dose. Normal HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 hrs post-dose.
| Milestone | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Area Under the Concentration-Time Curve
| ng*hr/mL | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|
| AUC0-24 | 1167 ± 53.6 | 226.1 ± 55.3 |
| AUC0-last | 1161 ± 53.9 | 220.0 ± 57.3 |
| AUC0-inf | 1169 ± 53.8 | 226.5 ± 55.1 |
Maximum Cmax
| ng/mL | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|
| Maximum Plasma Acalabrutinib Concentration | 726.0 ± 56.2 | 147.7 ± 116.8 |
Collected over From first dose of study drug until 30 days post last dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Severe Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Normal Hepatic Function | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 1/8 | 0/8 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/8 | 0/8 |
| Age, Continuous(Years) | Severe Hepatic Impairment | Normal Hepatic Function | Total |
|---|---|---|---|
| Mean | 57.6 ± 7.96 | 57.1 ± 4.88 | 57.4 ± 6.39 |
| Sex: Female, Male(Participants) | Severe Hepatic Impairment | Normal Hepatic Function | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 7 | 7 | 14 |
| Race/Ethnicity, Customized(Participants) | Severe Hepatic Impairment | Normal Hepatic Function | Total |
|---|---|---|---|
| Not Hispanic or Latino | 4 | 5 | 9 |
| Hispanic or Latino | 4 | 3 | 7 |
| Race/Ethnicity, Customized(Participants) | Severe Hepatic Impairment | Normal Hepatic Function | Total |
|---|---|---|---|
| Black or African American | 0 | 1 | 1 |
| White | 8 | 7 | 15 |
| Region of Enrollment(Participants) | Severe Hepatic Impairment | Normal Hepatic Function | Total |
|---|---|---|---|
| USA | 8 | 8 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2018 to primary completion in Mar 2019, 4 months.
Results were first posted in Sep 2021, 2 years 5 months after primary completion.
Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 4 months is below that.
Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib